ADVANCED SOLID TUMORS: PHASE 1: NKG2A inhibitor: CA047004

A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination with Nivolumab or
Cetuximab in Participants with Advanced Solid Tumors

Title
Bristol-Myers Squibb CA047004 (Phase 1 NKG2A inhibitor)
Study Title

A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination with Nivolumab or
Cetuximab in Participants with Advanced Solid Tumors

Site Link
Malignancy
Advanced Solid Tumors, renal cell, head and neck cancer (SCCHN), non-small cell lung cancer (NSCLC)
Stage
Disease Setting
ADVANCED/METASTATIC
Line Of Therapy
> or = 2nd line
Investigational Agent
BMS-986315 with either nivolumab or cetuximab
Drug Class
NKG2A inhibitor
PI
Dan Vaena, MD
Sponsor
Bristol-Myers Squibb
Phase
Status
Key Eligibility Criteria
Key Eligibility Criteria Details
  • Renal cell, NSCLC, or SCCHN
  • Must have received prior PD-1 or PD-L1 inhibitor
  • ECOG PS 0-1
  • No known autoimmune disease
  • No need for steroids or other immunsuppressive medicine
  • No interstitual lung disease or pulmonary fibrosis
Objective
  • Primary- 
    • AEs
    • SAEs
    • Number of deaths
  • Secondary
    • ORR
    • DoR
    • PFS
    • PK
Assessment Frequency
_
Assessment Frequency 2
_



Assessment Frequency Link
Path
Dosing Frequency
Control Agents
Study Protocol
Randomized
No
X